Citations

Clear

1413 citation(s) found for "To, Christina".

Angiotensin Converting Enzyme Inhibition and Mortality in Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH‐COPD)
Yogeswaran, Athiththan , Fünderich, Meike , Wendlandt, Katharina, Annis, Jeffrey , Brittain, Evan, Eichstaedt, Christina A., Cajigas, Héctor , Frantz, Robert P. , Sweatt, Andrew J. , Zamanian, Roham T., Wilhelm, J, Ghofrani, Hossein-Ardeschir, Tello, Khodr , Thenappan, Thenappan , Balasubramanian, Aparna , Sіrenko, Yu.M. , Cajigas, Hector R , Frantz, Robert P , Tello, Khodr , Seeger, Werner , Thenappan, Thenappan , Yogeswaran, Athiththan , Balasubramanian, Aparna , Eichstaedt, Christina A. , Grünig, Ekkehard , Zamanian, Roham T. , Grimminger, Friedrich , Wilhelm, Jochen, Ghofrani, Hossein Ardeschir , Seeger, Werner

Mayo Clinic

Pulmonary Circulation | July 16, 2026 | Volume: 16 | Issue: 3 | Pages: No page available

10.1002/pul2.70348 | PMID 42516688 Get It

ABSTRACT In 567 PH‐COPD patients from the PVRI GoDeep Meta‐Registry, ACE inhibitor use was associated with improved survival only in severe PH (PVR > 5 WU), supporting prospective trials targeting this high‐risk subgroup.
Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease
Soleimani‐Meigooni, David N. , Chiotis, Konstantinos, Allen, Isabel E., Rabinovici, Gil D., Joie, Renaud La , Group, Meta-Centiloid Study, Apostolova, Liana G. , Asken, Breton M., Benzinger, Th., Betthauser, Tobey J., Bluma, Marina, Bombois, Stephanie, Bourgeat, Pierrick, Bouteloup, Vincent , Braskie, Meredith N., Brendel, Matthias, Brickman, Adam M., Bryant, Natalie, Bullich, Santiago , Carrillo, Maria C., Casaletto, Kaitlin, Cash, David M., Chang, Chiung-Chih, CHANG, H L, Chao, Yishu , Collij, Lyduine E., Corrada, Maria M., Craft, Suzanne , Dickerson, Bradford C., Dubois, Bruno, Dufouil, Carole, Fajardo, Alfonso, Farrar, Gill , Fortea, Juan, Frings, Lars , Frisoni, Giovanni B., Gardner, Raquel C., Gnörich, Johannes , Gordon, Brian A., Gu, Yuna , Guan, Yihui, Guo, Tengfei, Hanseeuw, Bernard J., Hansson, Oskar, Harrison, Theresa M., Huang, Qi, Huang, ST , Iaccarino, Leonardo, Ishii, Kazunari, Ishi, Kenji, Jagust, William J., Johnson, Sterling C., Kato, Takashi, Katsumi, Yuta, Kaye, Jeffrey, Kolinger, Guilherme D., Kramer, Joel H. , Landau, Susan M., Landeau, Brigitte, Lao, Patrick J., Lee, Sangwon, Lopresti, Brian J., Lowe, Val J. , Luchsinger, José A., Mao, Xiaoxie, March, Andrew, Masters, Colin L., Meyer, Philipp T., Mezenge, Florence, Mormino, Elizabeth C., Franquesa‐Mullerat, María , Nakamura, Akinori, Nordberg, Agneta, O’Brien, John T., O’Bryant, Sid E., Pappas, Ioannis, Peretti, Debora E., Rowe, Christopher C., Rowe, James B., Schwartz, Daniel L., Seo, Sang Won , Shekari, Mahnaz, Smith, Ruben, Snyder, Heather M. , Sokolowski, Andrzej, Sperling, Reisa A., Sun, Pan, Taggett, Jacinda Z., Touroutoglou, Alexandra , Vaillancourt, David E., Giessen, Elsmarieke van de, Vijverberg, Jort, Villemagne, Victor L. , Villeneuve, Sylvia , Wang, Wei-en, Weiner, Michael, Woodworth, Davis, Xiao, Cally , Xie, F, Yoon, Yeojun, Yun, Mijin, Severanc, A4, ABIDE, ADNI*, ADNI-DoD, AgeWell, AIBL, AMYPAD, BACS, BATON, BIOCARD, BLSA, BioFINDER-2, BrANCH, CPAS, DETECT-AD, GEMS, GHABS, HABS, HABS-HD, IDEAS, IMAP, INSIGHT-preAD, Insight46, K-ROAD, LEADS, MCSA, MULNIAD, MEMENTO, SCAN, PREVENT-AD, SPIN,, Corrada, María M. , La Joie, Renaud , Blazhenets, Ganna , Chiotis, Konstantinos , Allen, Isabel Elaine , Rabinovici, Gil D. , Asken, Breton M. , Bejanin, Alexandre , Benzinger, Tammie L.S. , Betthauser, Tobey J. , Blūma, Marina , Bombois, Stéphanie , Bourgeat, Pierrick , Braskie, Meredith N. , Brendel, Matthias , Brickman, Adam M. , Carrillo, María C. , Casaletto, Kaitlin B. , Cash, David M. , Chang, Chiung‐Chih , Chang, Hsin‐I , Chêne, Geneviève , Chételat, Gaël , Coath, William , Collij, Lyduine , Colmant, Lise , Dickerson, Bradford Clark , Dubois, Bruno , Dufouil, Carole , Fortea, Juan , Garibotto, Valentina , Gordon, Brian A. , Guan, Yihui , Guo, Tengfei , Hanseeuw, Bernard , Hansson, Oskar , Harrison, Theresa M. , Iaccarino, Leonardo , Ishii, Kazunari , Ishii, Kenji, Jagust, William J. , Johnson, Sterling C. , Katsumi, Yuta , Kaye, Jeffrey , Koeppe, Robert A. , Kolinger, Guilherme Domingues , Landau, Susan , Landeau, Brigitte , Lao, Patrick , Lee, Sangwon, Lleó, Alberto , Lopresti, Brian J. , Malpetti, Maura , March, Andrew, Masters, Colin L. , Mézenge, Florence, Mormino, Elizabeth C. , Nakamura, Akinori , Nordberg, Agneta , O'Brien, John Tiernan , O’Bryant, Sid E. , Pappas, Ioannis , Quenon, Lisa , Rowe, Christopher Cleon , Rowe, James B. , Rudolph, Marc D. , Salvadó, Gemma , Schott, Jonathan M. , Schwarz, Christopher G. , Shekari, Mahnaz , Silbert, Lisa C. , Smith, Ruben, Sokolowski, Andrzej, Sperling, Reisa Anne , Sun, Pan , Taggett, Jacinda , Toga, Arthur W. , Vaillancourt, David E. , Giessen, Elsmarieke van de , Vemuri, Prashanthi , Villain, Nicolas , Wang, Wei‐en , Weiner, Michael W. , Xie, Fang , Young, Christina B. , Yun, M R

Mayo Clinic

JAMA | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jama.2026.13116 | PMID 42441390 Get It

Importance Amyloid positron emission tomography (PET) is increasingly used in research and clinical settings to determine the etiology of cognitive decline and eligibility for amyloid-targeting therapies. To assist with amyloid PET evaluation and to guide clinical decision-making, images can be quantified in a standardized unit called Centiloid, the interpretation of which can vary according to the method and threshold used. Objective To collect Centiloid values from available studies and determine robust positivity cutoffs using data-driven methods and correspondence with visual reads. Data Sources PubMed search (October 2024) identified studies with Centiloid values. Corresponding authors were invited to share individual participant data. Additional data were obtained through access-controlled repositories and conference outreach (July 2024-July 2025). Study Selection Studies were included if they provided Centiloids, radiotracer, age, and sex. Data Extraction and Synthesis Each study was analyzed using a unified statistical pipeline; study estimates were pooled using random-effects meta-analysis. Main Outcomes and Measures Gaussian mixture models (GMMs) were fitted to Centiloid values for each study. In studies with a bimodal distribution (per integrated completed likelihood), single cutoffs for positivity were set as mean plus 2 SDs of the lower gaussian component. Using GMMs, a double-cutoff approach defined a lower certainty range using a 90% posterior probability cutoff for assignment to the low (amyloid-negative) vs high (amyloid-positive) component. An alternative Centiloid cutoff was derived from maximizing the correspondence (Cohen κ) with the binary visual reads when available. Results This meta-analysis included cross-sectional amyloid PET scans acquired with 5 radiotracers from 49 227 participants across 53 studies from 15 countries (mean age, 71 years; 54% female, 62% cognitively impaired). The data-driven GMM approach identified a bimodal distribution in 51 studies (n = 48 786), resulting in a single cutoff for positivity of 18 Centiloids (95% CI,16-19; I 2 = 97%). The double-cutoff approach revealed high confidence for interpreting scans as negative when Centiloid values were lower than 11 (95% CI, 9-13; I 2 = 95%) and interpreting scans as positive if Centiloid values were higher than 26 (95% CI, 24-28; I 2 = 95%). In analyses of correspondence with binary (positive or negative) visual reads of amyloid PET scans (n = 35 045; 36 studies), Centiloids were highly predictive of visual positivity (Cohen κ, 0.86; 95% CI, 0.83-0.89; I 2 = 96%) with a cutoff of 27 Centiloids (95% CI, 24-30; I 2 = 80%). Conclusions and Relevance In this individual participant data meta-analysis, positivity cutoffs converged around 18 Centiloids (data-driven) and 27 Centiloids (visual reads). Findings from a double-cutoff analysis suggest that scans in the 11 to 26 Centiloid range should be interpreted with caution depending on the context of use.
Real-World Practice in Secondary Stroke Prevention Following Embolic Stroke of Undetermined Source
Nour, Hassan Aboul , Siegler, James E. , Thompson, Sean, Glover, Patrick , Daniel, J, Penckofer, Mary , Smith, M A, Yaghi, Shadi , Chen, L, Kerrigan, Deborah , Kirchhoffer, Kaitlyn, Kam, Wayneho , Melkumova, Emiliya , Lineback, Christina , Thottempudi, Neeharika , Heaton, Sharon, Linares, Guillermo , Singh, Eesha , Fernández, Camilo José Albert, Dumitrașcu, Oana , Bowman, Anna, Porto, Camelia Valhuerdi, Chahien, Dalia, Herpich, Franziska , Kang, Jieun , Nelson, Ashley , Shahrivari, Mahan, Khezri, Nicole, Lewis, Skylar, Sathya, Anvitha , Leung, Lester Y. , Eklund, Kelsey , Rojas-Soto, Diana , Nedelcu, Simona , Kasab, Sami Al , Coevering, Russell J. Van, Thon, Jesse , Aboul-Nour, Hassan , Siegler, James E , Thompson, Sean L , Glover, Patrick , Daniel, Jean-Philippe Auguste , Smith, Matthew M , Ro, Jennifer , Chen, Lucia , D'Souza, Marissa , Khasiyev, Farid , Kerrigan, Deborah , Sharma, Richa , Aziz, Yasmin , Kirchhoffer, Kaitlyn , Kam, Wayneho , Melkumova, Emiliya , Sloane, Kelly L , Lineback, Christina M , Thottempudi, Neeharika , Heaton, Sharon , Linares, Guillermo , Almallouhi, Eyad , Stretz, Christoph , Dumitrascu, Oana M , Culbertson, Collin J , Elangovan, Cheran , Bowman, Anna , Valhuerdi Porto, Camelia , Chahien, Dalia , Herpich, Franziska , Farooqui, Mudassir , Kang, Jieun , de Havenon, Adam H , Nelson, Ashley , Shahrivari, Mahan , Stamm, Brian , Khezri, Nicole , Lewis, Skylar , Sathya, Anvitha , Leung, Lester Y , Eklund, Kelsey , Rojas-Soto, Diana , Nedelcu, Simona , Al Kasab, Sami , Thon, Jesse , Jillella, Dinesh V , Nahab, Fadi B , Yaghi, Shadi , Penckofer, Mary , D’Souza, Marissa , Khasiyev, Farid , Sharma, Richa , Aziz, Yasmin , Almallouhi, Eyad , Stretz, Christoph , Elangovan, Cheran , Havenon, Adam de , Stamm, Brian , Coevering, Russell J. Van , Jillella, Dinesh

Mayo Clinic

Neurology Clinical Practice | July 10, 2026 | Volume: 16 | Issue: 4 | Pages: No page available

10.1212/cpj.0000000000200631 | PMID 42430672 Get It

Renal Function Decline After Vascularized Composite Allotransplantation
Ouellet, Gabriel , Sardu, Claudia , Kanitakis, Jean , Amer, Hatem, Azari, Kodi , Badet, Lionel , Brandacher, Gerald , Cendales, Linda, Özkan, Özlenen , Gaillard, Christophe , Gazarian, Aram, Kaufman, Christina , Landín, Luis , Lanzetta, Marco , Levin, L. Scott , Sassu, Paolo , Satbhai, Nilesh, Morélon, Emmanuel , Dogan, Ozlenen , Kaminska, Dorota , Lanzetta, Marco , Levin, Scott , Morales, Martin Iglesias , Sassu, Paolo , Talbot, Simon , Weissenbacher, Annemarie , Thaunat, Olivier , Morelon, Emmanuel , Petruzzo, Palmina , Amer, Hatem , Badet, L. , Cendales, Linda C. , Kamińska, Dorota , Lassus, Patrik , Iglesias, Martín , Weißenbacher, Annemarie , Thaunat, Olivier

Mayo Clinic

Transplantation Direct | July 6, 2026 | Volume: 12 | Issue: 8 | Pages: e1976

10.1097/txd.0000000000001976 | PMID 42416359 Get It

Background. Chronic kidney disease (CKD) is a common complication of nonrenal transplantation, influencing recipients’ morbidity and mortality. The incidence of CKD varies depending on the transplanted organ. Recipients of vascularized composite allotransplantation (VCA) need lifelong immunosuppression similar to that of solid organ transplantation. This study investigated renal function in VCA recipients. Methods. We studied 70 recipients from 17 centers (median follow-up: 8 y): 59 upper extremity, 10 face, and 1 penis transplant. Pretransplant and posttransplant clinical data and sera were collected to calculate the estimated glomerular filtration rate (eGFR) using the CKD Epidemiology collaboration 2021 formula. Results. Pretransplantation, the median eGFR was 105.36 mL/min (range, 71.39–155.39 mL/min). By 3 mo posttransplant, the eGFR had significantly decreased to 78.42 mL/min (range, 32.49–130.74 mL/min; P = 0.001) before stabilizing. Despite higher tacrolimus levels at 3 mo, no correlation with eGFR was found. During follow-up, 17.1% of patients experienced a ≥50% eGFR decline, 10.9% progressed to CKD, and 4.7% developed end-stage kidney disease. Some risk factors were identified, but their responsibility could not be established with certainty because of the low number of severe renal outcomes. Conclusions. Renal function declines in the majority of VCA recipients, but the function loss is lower compared with nonrenal solid organ transplantation recipients. Although no statistically significant correlation could be established between tacrolimus exposure and renal function decline, strategies aiming at minimizing calcineurin inhibitor exposure and avoiding other nephrotoxic causes are recommended to preserve long-term kidney function.
The Iron Lung: Ferroptosis and Iron Regulation in Aging and Lung Diseases
Ngassie, Maunick Lefin Koloko , Ortiz, Yamillie , Ravi, Preetham , Pfeffer-Kleemann, Daniel A., Borkar, Niyati A. , Pabelick, Christina M. , Prakash, Y. S. , Koloko Ngassie, Maunick Lefin , Pfeffer-Kleemann, Daniel , Borkar, Niyati , Pabelick, Christina M , Prakash, Y S

Mayo Clinic

Physiology | June 27, 2026 | Volume: 42 | Issue: 1 | Pages: 000-000

10.1152/physiol.00062.2025 | PMID 42363743 Get It

Iron is an important metal element regulating biological processes such as gene expression, electron transport, cell proliferation, differentiation and division, and cellular respiration. Regulation of iron levels is therefore critical, with excess iron accumulation leading to iron-dependent lipid peroxidation and cell death (ferroptosis). Factors such as aging and environmental exposures (e.g., high/low oxygen, particulate iron) can disrupt iron homeostasis. Iron-dependent processes influence downstream pathways such as inflammation, mitochondrial energetics, and remodeling (proliferation, fibrosis), pathways involved in lung diseases particularly at the extremes of age, from hyperoxic lung injury in neonates to chronic diseases such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis (PF) that increase with age. Although these diseases involve structural and functional changes in bronchial versus alveolar compartments, including airway hyperreactivity, altered mucus production, cell proliferation and migration, increased extracellular matrix (ECM) remodeling, senescence, and metabolic dysregulation, the casual or consequential links between iron dysregulation and disease pathology, particularly with aging, are still being investigated. The aim of this topical review is to 1) highlight current knowledge regarding iron regulation in normal lung versus lung diseases, 2) identify known roles of iron in lung homeostasis and the contribution of iron dysregulation in lung diseases with aging, and 3) explore the potential benefit of targeting iron regulation and/or ferroptosis in lung diseases.
Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with Emavusertib
Roemeling, Christina A. Von , Doonan, Bently P. , Carpenter, Savannah, Patel, Jeet A. , Jobin, Gabriel, Yang, Changlin , Bhatia, A. , Trivedi, Vrunda , Acevedo, A Buylla, Elliott, Tyler , Archibald, Vincent , Speakman, S, Matich, Erica , Mitchell, Duane A. , von Roemeling, Christina A , Carpenter, Savannah L , Jobin, Gabriel W , Bhatia, Alisha , Acevedo, Amanda , Speakman, Skye M , Doonan, Bently , Patel, Jeet A. , Archibald, Vincent

Mayo Clinic

Molecular Cancer Therapeutics | June 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/1535-7163.mct-25-0349 | PMID 42338303 Get It

Abstract Current advances in the treatment of melanoma brain metastases through immune checkpoint blockade and targeted therapy has significantly improved outcomes and patient survival. Yet, half of all patients continue to die from brain metastases despite use of these therapies and the addition of localized therapies like surgery and stereotactic radiosurgery. Novel treatments are needed to improve the morbidity and mortality associated with melanoma brain metastases. We have identified the inflammatory myddosomal pathway as a novel potential target of therapy in melanoma brain metastases, with gross upregulation in both tumor tissue and tumor-infiltrating immune cells. These cells display upregulation in MYD88, IRAK-1, IRAK-4, and downstream mediators of inflammatory activation at both the gene and protein level. We have previously shown the ability of the oral IRAK-4 inhibitor emavusertib (CA-4948) to penetrate the blood brain barrier and inhibit the myddosomal pathway in metastatic melanoma and primary CNS lymphoma. In this study we further show the capacity for IRAK-4 inhibition with emavusertib to improve the therapeutic efficacy of anti-PD-1 immune checkpoint blockade in melanoma brain metastases. Emavusertib in combination with anti-PD-1 therapy results in improved tumor-infiltrating lymphocyte recruitment, decreased myeloid derived suppressor cell function, and upregulation of interferon γ signaling resulting in improved survival in aggressive mouse models of melanoma brain metastases. This work supports the development of combination strategies of emavusertib with immune checkpoint blockade in melanoma brain metastases.
P257 Efficacy and safety up to 3 years of risankizumab in moderately to severely active ulcerative colitis patients: COMMAND interim results
Atreya, Raja, Louis, Edouard, Loftus, Edward V, Rubin, David T, Dubinsky, Marla C., Hisamatsu, T, Kalabic, Jasmina , Méndez, Paloma, Chen, S H, Shah, Saajan, Morisset, Pierre, Duan, W Rachel, Coll, Christina, Panaccione, Remo, Atreya, Raja Narayana , Rubin, David T. , Hisamatsu, Tadakazu, Mendez, Paloma, Morisset, Pierre, Duan, W Rachel, Panaccione, Remo

Mayo Clinic

E-Posters | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: A240.2-A241

10.1136/gutjnl-2026-bsg.373 Get It

P189 Efficacy and safety of upadacitinib maintenance treatment in patients with moderately to severely active crohn’s disease: 3-year results from U-ENDURE
Loftus, Edward V, D’Haens, Geert R, Louis, Edouard, Regueiro, Miguel D, Jairath, Vipul, Magro, Fernando, Nakase, Hiroshi, Dubcenco, Elena, Fish, Irina, Kim, Kimmie, Wang, Y , Anyanwu, Samuel I, Aponte, Fernando, Ogholikhan, Sina, Coll, Christina, Blumenstein, Irina, D’Haens, Geert R, Jairath, Vipul , Magro, F , Nakase, Hiroshi , Anyanwu, Samuel, Ogholikhan, Sina, Blumenstein, Irina

Mayo Clinic

E-Posters | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: A198.1-A198

10.1136/gutjnl-2026-bsg.315 Get It

Hyperoxia and iron homeostasis in developing human airway smooth muscle
Ortiz, Yamillie , Ngassie, Maunick Lefin Koloko , Bartman, Colleen M. , Pabelick, Christina M. , Prakash, Y. S. , Koloko Ngassie, Maunick Lefin , Prakash, Y S , Pabelick, Christina M , Bartman, Colleen M

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | June 18, 2026 | Volume: 331 | Issue: 2 | Pages: L144-L154

10.1152/ajplung.00027.2026 | PMID 42313077 Get It

Recognizing that antioxidant systems are impaired in the airways of premature infants, we used human fetal airway cells to explore the impact of oxygen on iron regulation and iron-mediated cell death (ferroptosis). We find moderate hyperoxia impairs antioxidant systems that prevent ferroptosis and dysregulates iron metabolism, while severe hyperoxia has a negative effect on mechanisms driving the early onset of ferroptosis. Inhibitors of ferroptosis decrease iron and lipid peroxidation, demonstrating links between oxygen and iron regulation in developing airways.